Rubinstein-Taybi syndrome (RSTS) is a multiple congenital anomalies syndrome associated with mutations in CREBBP (70%) and EP300 (5-10%). Previous reports have suggested an increased incidence of specific benign and possibly also malignant tumors.
the transcriptional co-activator CREB-binding protein (CREBBP) on chromosome 16p13.3 in about 60% of affected individuals (Petrij et al., 1995) , a submicroscopic deletion at 16p13.3 in about 10% of individuals (Hennekam, 2006) , or a mutation of the gene E1A binding protein p300 (EP300) on chromosome 22q13.2 in about 5-10% of individuals (Fergelot et al., 2016; Roelfsema et al., 2005) .
In the remaining RSTS individuals, no specific genetic alterations can be detected and the diagnosis is based on the combination of clinical manifestations only. Most mutations occur de novo although vertical transmission of mutations has been described (Hennekam, 2006) . CREBBP and EP300 are closely related proteins belonging to the K-acetyltransferase-3 (KAT3) family of histone/protein lysine acetyltransferases, which serve as transcriptional co-activators for a large number of DNA-binding transcription factors that mediate multiple signaling and developmental pathways (Wang et al., 2010) .
Mutations in CREBBP and EP300 have been demonstrated in various benign and malignant tumors, including in up to 40% of diffuse large cell B-cell lymphoma (DLBCL) and follicular lymphoma cases (Lohr et al., 2012; Morin et al., 2011; Pasqualucci et al., 2011; Zhang et al., 2011) . A specific type of acute myeloid leukemia is associated with a chromosomal translocation involving CREBBP (Rozman et al., 2004) .
Various benign and malignant tumors have been described in RSTS individuals. In 1989, Siraganian, Rubinstein, and Miller (1989) reported a series of 574 RSTS individuals in whom 22 tumors were detected in 19 persons (3.3%). Nine were malignant, 13 were benign, and 79% occurred under the age of 20. Miller and Rubinstein (1995) expanded the above series and reported 36 tumors in 725 RSTS individuals (5%). Tumors of the central nervous system and of hematological origin were relatively frequently reported (12 and 6 of 36 neoplasms, respectively) and two individuals with pilomatricomas were noted. For both studies, molecular confirmation of RSTS was not yet possible at the time of publication, preventing genotype-phenotype studies. Genotypephenotype studies have not been performed in subsequent reports either. The data in these series were composed of cases reported in literature and cases reported to Dr Jack Rubinstein (Miller & Rubinstein, 1995; Siraganian et al., 1989) .
Individuals with RSTS are prone to develop excessive scar tissue (keloids). In 24% of RSTS individuals, itching keloids develop during puberty and adulthood (van de Kar et al., 2014) . It has been suggested that, similarly to other neoplastic processes, keloids in RSTS individuals may also be a result of deregulated proliferation of fibroblasts and thereby may serve as a model to study in those individuals the earliest oncogenic changes (Siraganian et al., 1989; van de Kar et al., 2014) .
Here, we report the results of a study on the incidence of benign and malignant tumors and on possible genotype-phenotype correlations in a nation-wide, population-based study covering all known 
| PALGA database search for benign and malignant tumors in individuals with RSTS
Since 1985, all pathology reports are centrally archived in the nationwide network and registry of histopathology and cytopathology in the Netherlands (PALGA), with a nationwide coverage of all academic and non-academic hospitals since 1990 (Casparie et al., 2007) . Standardized coding allows for comprehensive searches for specific and detailed diagnoses and patient cohorts, while still compliant to current privacy regulations.
Using the name, sex, and date of birth, all histopathological and cytological pathology registrations of all known RSTS individuals were retrieved from the PALGA database. To identify relevant diagnoses that may not be diagnosed by histopathological or cytological examination, and therefore may not be registered in PALGA (e.g., acute leukemia), the database of the Netherlands Cancer Registry was searched using the same strategy. Medical data, including results of physical exams and presence of keloids, were retrieved from the files of one of the authors (RCH). Benign and malignant tumors were defined as described by Willis (1952) .
All relevant pathology slides were retrieved from the original pathology laboratories and reviewed by two experienced pathologists (PW, DDJ). Presence of keloid lesions was assessed predominantly on clinical grounds, as described elsewhere (van de Kar et al., 2014) and histologically confirmed if reported in the PALGA database.
All available genotype data for both CREBBP and EP300 mutations were obtained from the original diagnostic laboratories. All molecular studies had been performed as part of routine clinical work-up, no additional molecular studies were performed specifically for the present study. Only individuals with a proven variant in CREBBP or EP300 were included in analysis.
| Literature review of benign and malignant tumors in individuals with RSTS
A PubMed search was performed using the queries "Rubinstein-Taybi syndrome," "Rubinstein-Taybi syndrome," "Rubinstein-Taybi," and "Rubinstein-Taybi" as to cover all publications on RSTS. All retrieved publications, including individual case reports and case series, were scanned for tumors. The references in the publications were handsearched for further publications. Publications in other languages than English were excluded. There were no other exclusion criteria. Table 1; further details of all RSTS individuals are provided in Supplementary   Table S1 .
All RSTS diagnoses were confirmed based on clinical criteria by a single observer (RCH). Cytogenetic and/or molecular confirmation for CREBBP and EP300 has been performed only after this had become Table S1 Though the percentage of individuals with a malignant tumor was higher in specific age categories (Figure 1 ), numbers were too small to make a reliable comparison.
| Review of the literature
A PubMed search yielded 650 publications since the original report in 1963 (Rubinstein & Taybi, 1963) . Fifty-two papers contained data on additional individuals with RSTS with tumors and together these described 97 benign and malignant tumors in 89 individuals. This means that, including the present study, a total of 132 tumors have been reported in 115 individuals with RSTS. An overview of all reported tumors in RSTS is presented in Table 2 .
| Genotype-phenotype correlation
In 51 of the 87 RSTS individuals in the present cohort, information on the germline variant in CREBBP (n = 42) or EP300 (n = 3) was available.
Variants could be classified as missense mutations leading to single amino acid alterations (n = 4), large deletions and duplications (n = 18), nonsense and frameshift mutations resulting in early truncation (n = 18), and splice site mutations (n = 5). In three patients, a germline variant in CREBBP (n = 1) and EP300 (n = 2) was reported without further details and in eight patients no germline variant in either gene was found, despite a clinical diagnosis of RSTS. The CREBBP/EP300 mutation status was available in 28 RSTS individuals with a tumor reported in the literature, 10 missense mutations, 9 with truncating mutations, 7 with large deletions, 1 with a splice site mutation, and 1 with a translocation.
| DISCUSSION
In this nation-wide, population-based cohort of 87 Dutch individuals with RSTS, the incidence of benign and malignant tumors was assessed. In Dutch individuals with RSTS, various malignant tumors were observed. Per age category, the incidence is compared to the general Dutch population (IKNL, 2017), but small numbers preclude formal epidemiological risk assessment (Figure 1 ). The overall frequency of malignancies in the presently reported Dutch RSTS population (8.3% in those with proven variants, 4.6% overall) is higher than previously reported by Siraganian and Miller (1.5% and 2.3%, respectively) (Miller & Rubinstein, 1995; Siraganian et al., 1989) in individuals with an age distribution similar to the present cohort. As the same definition for malignant tumors was used by the latter authors as by us, this may be caused by the opportunity in the Netherlands of using a comprehensive, population-based, and nation-wide search strategy. However, as PALGA has a nationwide coverage since 1989 only, the number of tumors may still be an BOOT ET AL. In the present cohort, no single type of malignancy predominated.
One individual with medulloblastoma and one individual with DLBCL were observed at (expected) ages of 9 and 57 years, respectively. In literature, five cases of medulloblastoma and 11 hematological malignancies have been reported at ages of 4-9 years and 0-58 years, respectively. The selection bias in the overview due to using case reports and nonsystematically gathered case-series, prevents drawing any conclusions with respect to true frequencies of these tumors in individuals with RSTS or to associations between tumors and CREBBP/EP300 variants.
Meningiomas were present in 8.3% of molecularly proven Dutch RSTS individuals (4.6% of all Dutch RSTS individuals) and occur in <0.1% in the general Dutch population (Casparie et al., 2007; Wiemels, Wrensch, & Claus, 2010) , supporting an increased risk to develop meningioma in RSTS individuals (Bourdeaut et al., 2014; Miller & Rubinstein, 1995; Skousen, Wardinsky, & Chenaille, 1996) . This is further supported by presentation of two metachronous, independent meningiomas in a single individual in the present study, who has been reported before separately (Verstegen, van den Munckhof, Troost, & Bouma, 2005) .
Pilomatricomas were found frequently (16.7% of molecularly proven and 9.2% of all individuals in the present study group; 0.16% histopathological diagnoses in general population in the same time interval (Casparie et al., 2007) . Likely the incidence of pilomatricomas is even higher, since these are usually diagnosed on clinical Medulloblastoma 8 M n/a n/a n/a Evans, Burnell, Campbell, Gattamaneni, and Birch (1993); Miller and Rubinstein (1995) Medulloblastoma 9 M n/a n/a n/a Skousen et al. (1996) Medulloblastoma 9 M n/a n/a n/a Miller and Rubinstein (1995) Neuroblastoma 0 M CREBBP c.605dupC n/a de Kort, Conneman, and Diderich (2014) Neuroblastoma 0 M n/a n/a n/a Miller and Rubinstein (1995) Neuroblastoma 3 M n/a n/a n/a Siraganian et al. (1989) Neuroblastoma 7 F n/a n/a n/a Ihara, Kuromaru, Takemoto, and Hara (1999) Glioma n/a n/a n/a n/a n/a Lannering, Marky, and Nordborg (1990)
Glioma n/a M n/a n/a n/a Lannering et al. (1990) Oligodendroglioma 2 F n/a n/a n/a Siraganian et al. (1989) Neurilemmoma 13 M n/a n/a + Russell, Hoffman, and Bain (1971); Siraganian et al. Pheochromocytoma 10 F n/a n/a n/a Bonioli and Bellini (1992); Miller and Rubinstein (1995) Adrenocortical adenoma 22 F n/a n/a n/a Siraganian et al. (1989) Pinealoma 14 M n/a n/a n/a Siraganian et al. (1989) Pituitary adenoma 49 M n/a n/a n/a Miller and Rubinstein ( Meningioma 39 F n/a n/a n/a Bilir, Bilir, and Wilson (1990) Meningioma 39 F n/a n/a n/a Siraganian et al. (1989) Leukemia (ALL) 0 M n/a n/a n/a Shaheed, Khamaiseh, Rifai, and Abomelha (1999) Leukemia (ALL) 2 F n/a n/a n/a Siraganian et al. (1989) Leukemia (ALL) 3 M n/a n/a n/a Siraganian et al. (1989) Leukemia (ALL) 6 F n/a n/a n/a Siraganian et al. (1989) Leukemia (AML) 16 M n/a n/a n/a Jonas, Heilbron, and Ablin (1978); Siraganian et al. (1989) Lymphoma ( 
Genital
Embryonal carcinoma 1 F n/a n/a n/a Miller and Rubinstein (1995) Ovarian carcinoma (serous) h 29 F n/a n/a n/a Johannesen, Williams, Miller, and Tuller (2015) Endometrium adenocarcinoma h 29 F n/a n/a n/a Johannesen et al. (2015) MGSCST 14 M No deletion n/a n/a Kurosawa, Fukutani, Masuno, Kawame, and Ochiai (2002) Seminoma testis 27 M n/a n/a n/a Siraganian et al. (1989) Germ cell tumor testis 0 M CREBBP c.1824-1G>A n/a Butler et al. (2016) HSIL 31 F n/a n/a − Present study
15 F n/a n/a + Siraganian et al. (1989) Leiomyoma uterus 22 F n/a n/a n/a Present study Leiomyoma a 48 F n/a n/a − Present study
Dermoid cyst 5 M n/a n/a n/a Bozkirli et al. (2000) Teratoma ovary l 22 F n/a n/a n/a Miller and Rubinstein (1995) 
Soft tissue
Leiomyosarcoma n/a n/a n/a n/a n/a Stevens, Pouncey, and Knowles (2011) Leiomyosarcoma omentum 11 M n/a n/a n/a Miller and Rubinstein (1995) Rhabdomyosarcoma k 4 M n/a n/a n/a Siraganian et al. (1989) ; Sobel and Woerner (1981) Rhabdomyosarcoma 5 M n/a n/a n/a Miller and Rubinstein (1995) ; Ruymann et al. (1988) Hemangioendothelioma 1 F n/a n/a n/a Altintas and Cakmakkaya, (2004) Granular cell tumor 22 F n/a n/a n/a Burton, Kumar, and Bradford (1997) Giant cell tumor n/a n/a n/a n/a n/a Stevens et al. (2011) Circumscribed storiform collagenoma 8 M n/a n/a + Zavras, Mennonna, Maris, and Vaos (2016) Fibrolipoma a 46 F n/a n/a − Present study Leiomyoma duodenum k n/a M n/a n/a n/a Siraganian et al. (1989) ; Sobel and Woerner (1981) Other malignant tumors Colon cancer j 50 F None found n/a n/a Bartsch et al. (2005) Colon carcinoma 58 M CREBBP c.4561-2A>G + Present study
Thyroid cancer n/a n/a n/a n/a n/a Stevens et al. (2011) Thyroid cancer j 54 F None found n/a n/a Bartsch et al. (2005) Lung carcinoma (NSCLC) c 34 Milani et al. (2016) Renal tumor n/a n/a n/a n/a n/a Stevens et al. (2011) (Continues) Odontoma 7 F n/a n/a n/a Felgenhauer (1973); Siraganian et al. (1989) Parathyroid adenoma 18 F n/a n/a n/a Siraganian et al. (1989) Thymoma 11 M n/a n/a n/a Verhoeven, Tuinier, Kuijpers, Egger, and Brunner ( Breast cancer n/a F n/a n/a n/a Levitas and Reid (1998) Fibroadenoma breast 12 F n/a n/a n/a Cambiaghi, Ermacora, Brusasco, Canzi, & Caputo (1994); Miller and Rubinstein (1995) Pilomatricoma 12 F CREBBP t(2;16)(p13.3;p13.3) − Imaizumi and Kuroki (1991); Masuno et al. (1998) Pilomatricoma 12 M n/a n/a n/a Miller and Rubinstein (1995) n/a n/a n/a n/a n/a Stevens et al. (2011) Pilomatricoma n/a F CREBBP 6122_6125del n/a Chiang et al. (2009) 
Vascular
Angiofibroma 5 M n/a n/a n/a Siraganian et al. (1989) Angioma (cerebellum) n/a F n/a n/a n/a Thienpont et al. (2010) Soft tissue angioma n/a M EP300 Microdeletion 1-31 n/a Negri et al. (2015) Hamartoma (occipital) n/a n/a n/a n/a n/a Stevens et al. (2011) Hemangioma 15 M CREBBP c.406C>T − Present study Bartsch et al. (1999) Hemangioma (capillary) i n/a M n/a n/a n/a Sahiner, Senel, Erkek, Karacan, and Yoney (2009) Hemangioma ( Dermoid cyst eye 6 F n/a n/a + Siraganian et al. (1989) Glomus tumor m n/a M n/a n/a n/a Siraganian et al. (1989) Lacrimal caruncle nevus 28 M n/a n/a n/a Pogrzebielski, Piwowarczyk, Kohylarz, and Romanowska-Dixon (2007) Naevus depigmentosus g 6 F CREBBP c.2199delG n/a Yoo et al. (2015) Nevus 8 M n/a n/a n/a Schepis, Greco, Siragusa, Batolo, and Romano ( n/a Present study Nevus 40 F n/a n/a n/a Present study Spitznevus 20 F n/a n/a − Present study "a" to "m," Same individual having more than one tumor; Age, age at onset; n/a, data not available; M, male; F, female; ALL, acute lymphatic leukemia; AML, acute myeloblastic leukemia; MGSCST, malignant gonadal sex cord stromal tumor; NSCLC, non-small cell lung carcinoma; DLBCL, diffuse large B-cell lymphoma; HSIL, high-grade squamous intra-epithelial lesion of the cervix.
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| 605
In the present cohort, genotype-phenotype correlation could be studied in 48 individuals for whom information regarding the CREBBP and EP300 mutation status was available, and in literature similar data were available for 28 persons with RSTS. There was no obvious correlation between the incidence of tumors in general or specific tumor types with the location of variants within CREBBP.
Tumors may be somewhat more common in individuals carrying large deletions as such deletions occur in 10% of RSTS individuals only (van Belzen, Bartsch, Lacombe, Peters, & Hennekam, 2011) , but no firm conclusion is possible without data on much larger groups of RSTS individuals. A specific surveillance in children or adults with RSTS to detect tumors at an earlier age is not indicated based on presently available data.
In our cohort, we observed one patient with DLBCL (germinal center B-cell [GCB]-like subtype). Since somatic CREBBP mutation is a very frequent early event in follicular B-cell lymphoma and diffuse large B-cell lymphoma (Lohr et al., 2012; Morin et al., 2011; Pasqualucci et al., 2011; Zhang et al., 2011) , this case was studied for somatic CREBBP alterations (Stevens et al., 2017) . A somatic CREBBP mutation on one allele was found (His1438Asp, variant allele frequency [VAF] 25%), while the known germline mutation (CREBBP c.4837delG) was found in only 6% of sequence reads. These results should be interpreted as deletion of the germline mutated allele with an acquired, possibly subclonal alteration on the other allele in tumor cells. This may be suggestive of a tumor suppressor model for CREBBP in lymphoma.
Possible relations between somatic CREBBP/EP300 mutations in other tumors have been implied. A biallelic deletion of CREBBP in medulloblastoma has been demonstrated (Bourdeaut et al., 2014) , and somatic mutations have been detected in small numbers of breast and colon carcinomas well (Iyer, Ozdag, & Caldas, 2004) . Linking CREBBP/ EP300 to meningiomas and pilomatricomas would be very interesting, however to our knowledge, no literature to date is available regarding these tumors. More comprehensive research is required to study the possible role of CREBBP and EP300 in oncogenesis.
Based on a nationwide, population-based study, we conclude that 
